Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01729884 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01729884 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 3 participants.
The verdict
NCT01729884, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial studies how well vaccine therapy works in treating patients with stage IV hormone receptor positive breast cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.
Interventions
- BIOLOGICAL HER-2/neu peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01729884
The ClinicalTrials.gov registry entry for NCT01729884 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HER-2/neu peptide vaccine is the first listed.
NCT01729884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01729884 about?
NCT01729884 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer". This phase II trial studies how well vaccine therapy works in treating patients with stage IV hormone receptor positive breast cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.
What is the current status of trial NCT01729884?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2012-12.
What interventions are being tested in trial NCT01729884?
The interventions under investigation include: HER-2/neu peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01729884?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.